The TGF-beta — SMAD pathway is inactivated in cronic lymphocytic leukemia cells

Aim: To study the status of the tumor growth factor beta (TGFB) pathway in chronic lymphocytic leukemia (CLL) cells and to uncover molecular details underlying CLL cell genesis. Objects and Methods: The study was conducted on peripheral blood samples of patients with CLL using the following methods:...

Full description

Saved in:
Bibliographic Details
Published in:Experimental Oncology
Date:2017
Main Authors: Matveeva, A., Kovalevska, L., Kholodnyuk, I., Ivanivskaya, T., Kashuba, E.
Format: Article
Language:English
Published: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2017
Subjects:
Online Access:https://nasplib.isofts.kiev.ua/handle/123456789/138586
Tags: Add Tag
No Tags, Be the first to tag this record!
Journal Title:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Cite this:The TGF-beta — SMAD pathway is inactivated in cronic lymphocytic leukemia cells / A. Matveeva, L. Kovalevska, I. Kholodnyuk, T. Ivanivskaya, E. Kashuba // Experimental Oncology. — 2017 — Т. 39, № 4. — С. 286–290. — Бібліогр.: 26 назв. — англ.

Institution

Digital Library of Periodicals of National Academy of Sciences of Ukraine
_version_ 1862731739186593792
author Matveeva, A.
Kovalevska, L.
Kholodnyuk, I.
Ivanivskaya, T.
Kashuba, E.
author_facet Matveeva, A.
Kovalevska, L.
Kholodnyuk, I.
Ivanivskaya, T.
Kashuba, E.
citation_txt The TGF-beta — SMAD pathway is inactivated in cronic lymphocytic leukemia cells / A. Matveeva, L. Kovalevska, I. Kholodnyuk, T. Ivanivskaya, E. Kashuba // Experimental Oncology. — 2017 — Т. 39, № 4. — С. 286–290. — Бібліогр.: 26 назв. — англ.
collection DSpace DC
container_title Experimental Oncology
description Aim: To study the status of the tumor growth factor beta (TGFB) pathway in chronic lymphocytic leukemia (CLL) cells and to uncover molecular details underlying CLL cell genesis. Objects and Methods: The study was conducted on peripheral blood samples of patients with CLL using the following methods: RNA isolation, analysis of expression of transcription factors using RT2 profiler assay, bioinformatics analysis of publicly available data bases on expression. Results: We have shown that the TGFB — SMAD canonical pathway is not active in CLL cells. SMAD-responsive genes, such as BCL2L1 (BCL-XL), CCND2 (Cyclin D2), and MYC, are down-regulated in CLL cells compared with peripheral blood B cells of healthy donors. Conclusions: The TGFB-mediated signaling is not active in CLL cells due to low (or absent) expression of SMAD1, -4, -5, -9, and ATF-3. Expression and phosphorylation status of SMAD2 and -3 should be further elucidated in the future studies.
first_indexed 2025-12-07T19:27:41Z
format Article
fulltext
id nasplib_isofts_kiev_ua-123456789-138586
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
issn 1812-9269
language English
last_indexed 2025-12-07T19:27:41Z
publishDate 2017
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
record_format dspace
spelling Matveeva, A.
Kovalevska, L.
Kholodnyuk, I.
Ivanivskaya, T.
Kashuba, E.
2018-06-19T10:03:11Z
2018-06-19T10:03:11Z
2017
The TGF-beta — SMAD pathway is inactivated in cronic lymphocytic leukemia cells / A. Matveeva, L. Kovalevska, I. Kholodnyuk, T. Ivanivskaya, E. Kashuba // Experimental Oncology. — 2017 — Т. 39, № 4. — С. 286–290. — Бібліогр.: 26 назв. — англ.
1812-9269
https://nasplib.isofts.kiev.ua/handle/123456789/138586
Aim: To study the status of the tumor growth factor beta (TGFB) pathway in chronic lymphocytic leukemia (CLL) cells and to uncover molecular details underlying CLL cell genesis. Objects and Methods: The study was conducted on peripheral blood samples of patients with CLL using the following methods: RNA isolation, analysis of expression of transcription factors using RT2 profiler assay, bioinformatics analysis of publicly available data bases on expression. Results: We have shown that the TGFB — SMAD canonical pathway is not active in CLL cells. SMAD-responsive genes, such as BCL2L1 (BCL-XL), CCND2 (Cyclin D2), and MYC, are down-regulated in CLL cells compared with peripheral blood B cells of healthy donors. Conclusions: The TGFB-mediated signaling is not active in CLL cells due to low (or absent) expression of SMAD1, -4, -5, -9, and ATF-3. Expression and phosphorylation status of SMAD2 and -3 should be further elucidated in the future studies.
We thank Professor Danylo Gluzman (R.E. Kavetsky IEPOR of NAS of Ukraine) for the fruitful discussions over this manuscript. This work was supported by the Swedish Cancer Society, by matching grants from the Concern Foundation (Los Angeles, USA) and the Cancer Research Institute (New York, USA), and by the Academy of Science of Ukraine (grant No. 0112U002192).
en
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
Experimental Oncology
Original contributions
The TGF-beta — SMAD pathway is inactivated in cronic lymphocytic leukemia cells
Article
published earlier
spellingShingle The TGF-beta — SMAD pathway is inactivated in cronic lymphocytic leukemia cells
Matveeva, A.
Kovalevska, L.
Kholodnyuk, I.
Ivanivskaya, T.
Kashuba, E.
Original contributions
title The TGF-beta — SMAD pathway is inactivated in cronic lymphocytic leukemia cells
title_full The TGF-beta — SMAD pathway is inactivated in cronic lymphocytic leukemia cells
title_fullStr The TGF-beta — SMAD pathway is inactivated in cronic lymphocytic leukemia cells
title_full_unstemmed The TGF-beta — SMAD pathway is inactivated in cronic lymphocytic leukemia cells
title_short The TGF-beta — SMAD pathway is inactivated in cronic lymphocytic leukemia cells
title_sort tgf-beta — smad pathway is inactivated in cronic lymphocytic leukemia cells
topic Original contributions
topic_facet Original contributions
url https://nasplib.isofts.kiev.ua/handle/123456789/138586
work_keys_str_mv AT matveevaa thetgfbetasmadpathwayisinactivatedincroniclymphocyticleukemiacells
AT kovalevskal thetgfbetasmadpathwayisinactivatedincroniclymphocyticleukemiacells
AT kholodnyuki thetgfbetasmadpathwayisinactivatedincroniclymphocyticleukemiacells
AT ivanivskayat thetgfbetasmadpathwayisinactivatedincroniclymphocyticleukemiacells
AT kashubae thetgfbetasmadpathwayisinactivatedincroniclymphocyticleukemiacells
AT matveevaa tgfbetasmadpathwayisinactivatedincroniclymphocyticleukemiacells
AT kovalevskal tgfbetasmadpathwayisinactivatedincroniclymphocyticleukemiacells
AT kholodnyuki tgfbetasmadpathwayisinactivatedincroniclymphocyticleukemiacells
AT ivanivskayat tgfbetasmadpathwayisinactivatedincroniclymphocyticleukemiacells
AT kashubae tgfbetasmadpathwayisinactivatedincroniclymphocyticleukemiacells